ReachMD

Which breast cancer findings from ASCO 2026 are most relevant to your practice?

ASCO 2026 featured important research that may influence care across a range of patient populations. In this video brief, Dr. Aditya Bardia highlights notable studies, discusses their clinical implications, and explores how emerging data may inform treatment decision-making and patient care.

Explore the clinical implications of the latest breast cancer research: https://ow.ly/qkC550ZejxP

Could emerging therapies have a role in maladaptive FSGS?

This discussion explores how therapies under review may extend beyond primary FSGS to what is now referred to as maladaptive FSGS. Early observations suggest potential applicability, highlighting an area of interest for future clinical use.

Explore how these insights may shape patient care: https://ow.ly/vs0p50YFHB0

Future Directions in FSGS Care Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that...

Biomarker-guided decision-making remains central to individualized ovarian cancer care. Join this broadcast for expert discussion on treatment selection, sequencing strategies, and adverse event management across the care continuum.

Register now: https://ow.ly/HW4L50ZcPIt

Tomorrow: Join Dr. Marc Oliva live as he dives into clinical evidence, treatment sequencing, and multidisciplinary coordination in resectable, locally advanced head and neck squamous cell carcinoma.

Register now: https://ow.ly/6ZAk50Zb95f

Don't miss the remaining two dates for a live broadcast on treating early symptomatic Alzheimer's disease. Faculty discuss standardized processes for therapy initiation, ARIA risk mitigation, and MRI-based monitoring to support safe and consistent care. This is a Worldwide Webinar Series, with subtitles available in French, Spanish, German, and Portuguese! Wherever you're located, we have an opportunity for you to join: https://ow.ly/Js5U50Z4q2j

Join a leading Spanish expert for a live, interactive webinar series exploring how perioperative immunotherapy may shape evolving treatment strategies in resectable, locally advanced HNSCC. He'll cover patient selection, sequencing approaches, multidisciplinary care integration, and more. Register now: https://ow.ly/sxiG50Zb7Xk

How should adjuvant therapy be optimized for patients with HER2-positive early breast cancer who remain at high risk after neoadjuvant treatment? The phase 3 DESTINY-Breast05 trial compared T-DXd with T-DM1 and helped inform updated NCCN guidance.

Explore the data in this video brief from ASCO 2026: https://ow.ly/SqlJ50ZabNV